NICE expands breast cancer drug options

The National Institute for Health and Clinical Excellence has announced that it is recommending the use of the hormonal therapies anastrozole, exemestane and letrozole for the treatment of women with early oestrogen receptor-positive invasive breast cancer following surgery to remove the tumours.The drugs will be available alongside existing breast cancer ...

You need to be signed in to read more


Subscribe for unlimited access

With a HSJ subscription you’ll unlock:

  • All of and our HSJ mobile app
  • News and insight on all areas of public funded healthcare
  • Expert commentary, insight and analysis from industry leaders
  • 9 weekly ‘Expert Briefing’ insight emails covering a variety of specialist topics

Sign into your account here